Alphabet's AI drug-discovery company Isomorphic Labs is in talks to raise about 5 billion dollars at a roughly 50 billion dollar valuation, according to Bloomberg. If the deal closes, it would become one of Europe's largest private financings and bring cumulative external funding to about 7.7 billion dollars in under two years.
A Blockbuster Round
People familiar with the matter said Isomorphic is discussing a raise of about 5 billion dollars that would imply a valuation near 50 billion dollars, with roughly 10 percent equity being sold. The company already completed a 2.1 billion dollar Series B in May 2026 led by Thrive Capital with Alphabet participating, so a close would push external funding past 7.7 billion dollars.
The DeepMind Connection
Isomorphic Labs was spun out of Google DeepMind in 2021 to apply AI to drug discovery. Its work builds on the AlphaFold protein-structure breakthroughs, aiming to shorten the long and costly path from target identification to candidate molecules. A valuation of this size reflects investor belief that AI can materially compress pharmaceutical timelines.
Why It Matters for Drug Discovery
If the financing holds, it would rank among the largest European private rounds on record and underline how heavily capital is flowing into AI-enabled biology. The bet is that generative models can design and validate therapeutics faster than traditional pipelines, though clinical proof at scale remains the open question.
Key Data Points
- About 5 billion dollars reportedly being raised
- Roughly 50 billion dollar implied valuation if the deal closes
- About 10 percent equity being sold
- About 7.7 billion dollars cumulative external funding in under two years
Sources: Bloomberg, WeChat public accounts; threerouter
Read the full story on ThreeRouter AI Daily: https://www.threerouter.com/blog/342
Published via ThreeRouter AI Daily. Cover image generated by AI; no Chinese text.

Top comments (0)